- Lorazepam and diazepam showed equivalent efficacy in managing alcohol withdrawal in a randomised symptom triggered oral detoxification protocol.
- Time to >50% symptom reduction was slightly shorter with diazepam, but the difference was not statistically significant.
- Both drugs improved anxiety and depressive symptoms, with numerically greater reductions with lorazepam but no statistically significant differences at postdetoxification and 12 weeks.
Prim Care Companion CNS Disord. 2026 May 26;28(3):25m04143. doi: 10.4088/PCC.25m04143.
ABSTRACT
Objective: To compare the efficacy of lorazepam and diazepam in managing alcohol withdrawal and associated anxiety and depressive symptoms in alcohol dependence syndrome.
Methods: Sixty male patients diagnosed with alcohol dependence syndrome (International Classification of Diseases, Eleventh Revision) were randomly assigned to receive lorazepam or diazepam using a symptom-triggered oral detoxification protocol. Baseline assessments included the Severity of Alcohol Dependence Questionnaire (mean score = 22.6 ± 4.81) and the Clinical Institute Withdrawal Assessment for Alcohol-Revised (mean CIWA-Ar score= 10.98±2.45). Anxiety and depression were measured using the Hamilton Anxiety Rating Scale (HAM-A) and Hamilton Depression Rating Scale (HAM-D) at baseline, postdetoxification, and 12 weeks. Benzodiazepines were gradually tapered and stopped after detoxification.
Results: Participants (mean age of 40.85 ± 8.30 years) showed comparable baseline withdrawal severity (CIWA-Ar P = .795) and similar reductions after detoxification (P = .999) and at 12 weeks (P = .321). Time to >50% symptom reduction was slightly shorter with diazepam (4.6 vs. 4.97 days; P = .241). Both groups demonstrated improvement in anxiety and depression, with slightly greater reductions in the lorazepam group, though differences were not statistically significant (HAM-A: P = .146; HAMD-D: P = .103).
Conclusions: Lorazepam and diazepam are equally effective in managing alcohol withdrawal.
Trial Registration: Clinical Trial Registry-India identifier: CTRI/2023/09/057998.
Prim Care Companion CNS Disord 2026;28(3):25m04143.
PMID:42214083 | DOI:10.4088/PCC.25m04143
AI Search
Share Evidence Blueprint

Search Google Scholar
Save as PDF

